tbuckley/cabot-search huggingface dataset:
P51.05 Sequential Afatinib and Osimertinib in Patients With Advanced EGFRm+ NSCLC and Acquired T790M: The Real-World UpSwinG study
Authors: S. Popat, H.A. Jung, S.Y. Lee, M.J. Hochmair, S.H. Lee, C. Escriu, M.K. Lee, M.R. Migliorino, Y.C. Lee, N. Girard, H. Daoud, A. Märten, S. Miura
Journal: Journal of Thoracic Oncology (2021)
P47.09 Tepotinib + Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2
Authors: C. Dooms, E. Nadal, J. Raskin, I. Demedts, J. Mazieres, M. Wislez, S. Abdul, T.L. Mun, C. Wang, S. Viteri, X. Le, S.H. How, D. Tan, M. Takeda, R. Veillon, N. Karachaliou, B. Ellers-Lenz, E. Smit, Y. Wu
Journal: Journal of Thoracic Oncology (2021)
Lessons from <i>Toxoplasma</i>: Host responses that mediate parasite control and the microbial effectors that subvert them
Authors: Eva-Maria Frickel, Christopher A. Hunter
Journal: The Journal of Experimental Medicine (2021)

The intracellular parasite Toxoplasma gondii has long provided a tractable experimental system to investigate how the immune system deals with intracellular infections. This review highlights the advances in defining how this organism was first detected and the studies with T. gondii that contribute to our understanding of how the cytokine IFN-γ promotes control of vacuolar pathogens. In addition, the genetic tractability of this eukaryote organism has provided the foundation for studies into the diverse strategies that pathogens use to evade antimicrobial responses and now provides the opportunity to study the basis for latency. Thus, T. gondii remains a clinically relevant organism whose evolving interactions with the host immune system continue to teach lessons broadly relevant to host–pathogen interactions.
Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder
Authors: Linmarie Sikich, Alexander Kolevzon, Bryan H. King, Christopher J. McDougle, Kevin B. Sanders, Soo-Jeong Kim, Marina Spanos, Tara Chandrasekhar, M.D. Pilar Trelles, Carol M. Rockhill, Michelle L. Palumbo, Allyson Witters Cundiff, Alicia Montgomery, Paige Siper, Mendy Minjarez, Lisa A. Nowinski, Sarah Marler, Lauren C. Shuffrey, Cheryl Alderman, Jordana Weissman, Brooke Zappone, Jennifer E. Mullett, Hope Crosson, Natalie Hong, Stephen K. Siecinski, Stephanie N. Giamberardino, Sheng Luo, Lilin She, Manjushri Bhapkar, Russell Dean, Abby Scheer, Jacqueline L. Johnson, Simon G. Gregory, Jeremy Veenstra-VanderWeele
Journal: New England Journal of Medicine (2021)

Experimental studies and small clinical trials have suggested that treatment with intranasal oxytocin may reduce social impairment in persons with autism spectrum disorder. Oxytocin has been administered in clinical practice to many children with autism spectrum disorder.
72P Targeting androgen receptor splice variant 7 in 22Rv1 prostate cancer cells
Authors: A.M. Scherbakov, M. Barysevich, M. Laktsevich-Iskryk, O.E. Andreeva, D.V. Sorokin, D.I. Salnikova, A. Hurski, V. Zhabinskii, V. Khripach
Journal: Annals of Oncology (2021)
Abstract 16197: Coronary Artery Calcium Among Adults With Borderline ASCVD Risk (5-7.5%): The Coronary Artery Calcium Consortium
Authors: S M Iftekhar Uddin, Albert D Osei, Sina Kianoush, Olusola Orimoloye, Mohammadhassan Mirbolouk, Zeina Dardari, Omar Dzaye, Michael Miedema, John Rumberger, Leslee Shaw, Daniel Berman, Michael Budoff, Alan Rozanski, Khurram Nasir, Michael J Blaha
Journal: Circulation (2019)

Introduction: Coronary artery calcium (CAC) is a strong predictor of future cardiovascular disease (CVD) events including among adults in the intermediate risk group of ASCVD 7.5-20%. The 2018 AHA/...
Government’s “rescue package” will prompt more GPs to quit, leaders warn
Authors: Gareth Iacobucci
Journal: BMJ (2021)

A new government blueprint designed to improve access to general practice will prompt more doctors to quit and shows that ministers are “completely out of touch” with the scale of the crisis in the profession, GP leaders have warned.

The plan,1 published on 14 October by the Department of Health and NHS England and NHS Improvement, pledges an extra £250m to increase the proportion of appointments practices deliver face-to-face and tackle the “unacceptably poor access to general practice” experienced by some patients.2

“A minority of practices are now offering wholly inappropriate access, with very low levels of face-to-face care,” the document said. “In August 2021 over 15% of practices recorded less than 20% of their GP appointments being held face-to-face. That is likely to be contrary to good clinical practice, even if it were to reflect the preferences of their patients.”

The plan …
The use of cannabinoid and non-cannabinoid supplementary therapies in patients undergoing treatment for Glioblastoma reveals an urgent need for guidance
Authors: Babar Vaqas, Louise Dulley, Ruchi Maniar
Journal: Neuro-Oncology (2021)

Abstract Aims Glioblastoma (GBM) is currently an incurable malignancy with a very poor prognosis for the majority of patients. Many patients undergo debulking surgery, radiotherapy and chemotherapy however therapeutic options are limited, and this can lead to patients sourcing their own treatments. There is some evidence that cannabinoids have the effect of inhibiting GBM tumour growth through a variety of pathways, some of which include CB2 cannabinoid receptor pathway activation. We undertook a patient questionnaire to understand what alternative therapies patients are accessing and why, with a focus on cannabinoid use. Method We undertook a prospective observational questionnaire based qualitative study of 50 … consecutive patients undergoing treatment for glioblastoma at our centre. Results 43 patients responded to our questionnaire. 33% of patients were taking some kind of supplementary therapy with 25% taking cannabis derivatives, mainly CBD oil. There were no clear discriminators amongst our cohort including age or sex when considering the likelihood of taking cannabis derivatives. 6 out of 11 (55%) patients taking cannabis derivatives reported some positive effects with improved sleep and general wellbeing being most commonly reported. Patients reported spending between £10-£300 per month with an average of £42 per month. Cannabis products were obtained via the internet or from friends. Conclusion This small cohort of patients indicates that a significant proportion of glioblastoma patients investigate and use alternative therapies, in particular cannabis oil. NICE guidance for clinicians simply notes there is insufficient evidence to support the use of cannabis oil in the treatment of this disease. Given the publicity and interest in the utility of cannabis oil to treat cancers this leaves patients to research the use of these agents without access to robust clinical data to guide their use or indeed to conclude they are not beneficial. The accessing of these compounds, potentially by a sizeable number of patients, leaves them vulnerable to unregulated perhaps unscrupulous drug sources. This small study has further highlighted the unmet need for information and guidance on supplementary treatments for glioma patients and this poses a challenge to all those treating this group of patients to answer a question our patients are clearly wanting answered.
Safety and tolerability of mRNA COVID-19 vaccines in people with antiphospholipid antibodies
Authors: Savino Sciascia, Piera Costanzo, Massimo Radin, Karen Schreiber, Massimo Pini, Antonella Vaccarino, Irene Cecchi, Simone Baldovino, Dario Roccatello
Journal: The Lancet Rheumatology (2021)
MA16.07 Prognostic Value of 18F-Fluorodeoxyglucose Uptake of Bone Marrow on PET/CT in Patients with Limited Disease Small Cell Lung Cancer
Authors: M. Ayık Türk, B. Kömürcüoğlu, A. Yanarateş, U. Yılmaz
Journal: Journal of Thoracic Oncology (2021)
Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas
Authors: Stefan R. Sweha, Chan Chung, Siva Kumar Natarajan, Pooja Panwalkar, Matthew Pun, Amer Ghali, Jill Bayliss, Drew Pratt, Anand Shankar, Visweswaran Ravikumar, Arvind Rao, Marcin Cieslik, Kari Wilder-Romans, Andrew J. Scott, Daniel R. Wahl, Selin Jessa, Claudia L. Kleinman, Nada Jabado, Alan Mackay, Chris Jones, Daniel Martinez, Mariarita Santi, Alexander R. Judkins, Viveka Nand Yadav, Tingting Qin, Timothy N. Phoenix, Carl J. Koschmann, Suzanne J. Baker, Arul M. Chinnaiyan, Sriram Venneti
Journal: Science Translational Medicine (2021)

Histone H3.3G34R/V mutant gliomas demonstrate LIF/STAT pathway activation that can be disrupted for therapeutic benefit.
MAPK inhibition via MEK, EGFR, or erbB-2 leads to return of estrogen-dependence and anti-estrogen response in ERα- breast cancer
Authors: Prakash Vishnu, Jill Bayliss, Amy Hilger, Kathleen Diehl, Dorraya El-Ashry
Journal: Cancer Research (2007)

2515  The estrogen receptor alpha (ERα) status of a breast tumor is very important, with ERα+ tumors responding to anti-estrogen therapy and having a better prognosis. In ERα- tumors, overexpression/amplification/hyperactivation of the erbB family leads to increased downstream signaling including hyperactivation of mitogen-activated protein kinase (MAPK) compared to ERα+ tumors. Using cell line models that mimic this elevated growth factor signaling by EGFR and erbB-2 in MCF-7 breast cancer cells, we have previously shown that hyperactivation of downstream p42/44 MAPK results in the reversible loss of ERα expression. Recently, we established a MAPK gene profile from these cell line models which accurately predicts ERα- breast cancer further demonstrating the link between hyperactive MAPK and the ERα- phenotype. In this study, we set out to ascertain the role of these mechanisms in established ERα- breast cancer cell lines and in ERα- tumor specimens. In ERα- cell lines with overexpression of EGFR or erbB-2 and a dependence upon MAPK for proliferation, re-expression of ERα upon MAPK inhibition correlated with a restoration of estrogen-dependence and anti-estrogen sensitivity. However, in a cell line with no dependence on MAPK for proliferation, the re-expressed ERα could not restore anti-estrogen sensitivity. Interestingly, in ERα- breast cancer cell lines with a basal rather than luminal phenotype, MAPK inhibition could not restore ERα expression suggesting that more permanent repression mechanisms such as ERα promoter hypermethylation are responsible for the ERα- phenotype in these cell types. Dissociated tumor cell cultures established from ERα- tumors confirm the ability of MAPK inhibition to restore ERα expression in ERα- tumors. In addition to direct MAPK inhibition, upstream inhibition of the overexpressed EGFR with gefitinib or erbB-2 with trastuzamab were equally effective in restoring ERα expression. Importantly, re-expression of ERα restored both estrogen dependence and anti-estrogen sensitivity. These data suggest that we need to alter our interpretation of ERα status - rather than thinking of ERα expression as being positive or negative, we need to think of it as a dynamic event that is strongly impacted by other cellular signaling pathways. Collectively, these data support our hypothesis that there exists a population of ERα- tumors where upregulated growth factor signaling is directly involved in the generation of the ERα- phenotype by repressing ERα expression and that further, this reversible downregulation may be targeted clinically such that this repression can be reversed by inhibiting MAPK, resulting in re-expression of ERα and restoration of tamoxifen sensitivity.
Generalizability of the Results and Concerns About Leakage Rates of the ICAN Trial
Authors: Rigved Nittala, Devyani Niyogi, George Karimundackal
Journal: JAMA Surgery (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Genome profiles of pathologist-defined cell clusters by multiregional LCM and G&amp;T-seq in one triple-negative breast cancer patient
Authors: Zhongyi Zhu, Weiwei Wang, Feng Lin, Tracy Jordan, Guibo Li, Sveta Silverman, Si Qiu, Anil Abraham Joy, Chao Chen, Deanna L. Hockley, Xi Zhang, Qing Zhou, Lynne M. Postovit, Xiuqing Zhang, Yong Hou, John R. Mackey, Bo Li, Gane Ka-Shu Wong
Journal: Cell Reports Medicine (2021)

Pathological examination is the gold standard for cancer diagnosis, and breast tumor cells are often found in clusters. We report a case study on one triple-negative breast cancer (TNBC) patient, analyzing tumor development, metastasis, and prognosis with simultaneous DNA and RNA sequencing of pathologist-defined cell clusters from multiregional frozen sections. The cell clusters are isolated by laser capture microdissection (LCM) from primary tumor tissue, lymphatic vessels, and axillary lymph nodes. Data are reported for a total of 97 cell clusters. A combination of tumor cell-cluster clonality and phylogeny reveals 3 evolutionarily distinct pathways for this patient, each associated with a unique mRNA signature, and each correlated with disparate survival outcomes. Hub gene analysis indicates that extensive downregulation of ribosomal protein mRNA is a potential marker of poor prognosis in breast cancer.
P10.09 Efficacy and Toxicity of EGFR-TKI in Frail NSCLC with EGFR Mutation: A Retrospective Analysis in a Single Institution
Authors: Y. Akazawa, A. Yoshikawa, K. Hashimoto, M. Kanazu, Y. Yano, T. Yamaguchi, M. Mori
Journal: Journal of Thoracic Oncology (2021)
P40.05 Radiation-Related Platelet Reduction in Patients With Stage IV Lung Cancer
Authors: Z. Liang, C. Zhao, F. Zhang, W. Xu, L. Xu, Y. Zhang, W. Chen, J. Zha, Y. Han, Y. Qu, Q. Wang, J. Zhang, L. Yang, F.M. Kong
Journal: Journal of Thoracic Oncology (2021)
Aging, Aortic Stenosis, and Transthyretin Cardiac Amyloidosis
Authors: Sabahat Bokhari, Rahul Gupta
Journal: JACC CardioOncology (2021)

ystemic amyloidosis is a rare, progressive, multisystem disease characterized by extracellular deposition of insoluble amyloid fibrils.Cardiac amyloidosis (CA) occurs when these fibrils deposit within the myocardial extracellular space.If untreated, this leads to infiltrative cardiomyopathy, heart failure, and death.Advances in echocardiography, cardiac magnetic resonance (CMR), and bone scintigraphy have led to improved diagnoses of CA.
Adult social care in England: revive the role of gerontological nurse specialist
Authors: Ala K Szczepura, Deidre Wild, Rosie Kneafsey
Journal: BMJ (2021)

Glasby argues that current government proposals on adult social care will not improve quality of care or the conditions of an underpaid and demoralised workforce.1 Similarly, Oliver states that older people with conditions like frailty or age related disabilities will continue to be treated as second class citizens compared with those with “healthcare” conditions.23

The pandemic has provided an opportunity to reimagine care homes and improve …
MA15.05 Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients in The U.S. ALCHEMIST Study (Alliance)
Authors: K. Kehl, D. Zahrieh, P. Yang, S. Hillman, A. Tan, J. Sands, G. Oxnard, E. Gillespie, D. Wigle, S. Malik, T. Stinchcombe, S. Ramalingam, K. Kelly, S. Mandrekar, R. Osarogiagbon, D. Kozono
Journal: Journal of Thoracic Oncology (2021)
Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 Mutations
Authors: Zishuo I Hu, Markku Miettinen, Martha Quezado, Alexandra P Lebensohn, Kenneth Aldape, Maria Agra, Cathy Wagner, Yvonne Mallory, Raffit Hassan, Azam Ghafoor
Journal: Journal of Thoracic Oncology (2021)
Spiking immunotherapy with a bacterial cocktail brings T cells back to the fight
Authors: K. Leigh Greathouse, Ankan Choudhury
Journal: Cell Reports Medicine (2021)

A recent study by Montalban-Arques et al.1 in Cell Host & Microbe shows that augmenting the function of the gut microbiota reduces tumor burden. Four Clostridiales species blocked tumor growth as efficient as chemotherapy or immunotherapy in colorectal cancer and melanoma.
Racially Segregated Schooling and the Cognitive Health of Black Adults in the United States—Why It Matters
Authors: Paris B. Adkins-Jackson, Jennifer Weuve
Journal: JAMA Network Open (2021)

Rachel L. Peterson, PhD, MPH, MA; Kristen M. George, PhD, MPH; Lisa L. Barnes, PhD; Paola Gilsanz, ScD; Elizabeth Rose Mayeda, PhD, MPH; M. Maria Glymour, ScD; Dan M. Mungas, PhD; Rachel A. Whitmer, PhD
FP16.03 Early Circulating-Tumor DNA EGFR Mutation Clearance in Plasma as a Predictor of Clinical Outcomes in The AURA3 Trial
Authors: M. Ahn, R. Hartmaier, Y. Wu, J. Han, H. Akamatsu, T. John, J.C. Yang, F.A. Shepherd, A. Delmonte, X. Huang, A. Mellemgaard, A. Markovets, J. Chmielecki, S. Ramalingam
Journal: Journal of Thoracic Oncology (2021)
Metabolomic differences in lung function metrics: evidence from two cohorts
Authors: Rachel S. Kelly, Isobel D. Stewart, Haley Bayne, Priyadarshini Kachroo, Avron Spiro, Pantel Vokonas, David Sparrow, Scott T. Weiss, Hanna M. Knihtilä, Augusto A. Litonjua, Nicholas J. Wareham, Claudia Langenberg, Jessica A. Lasky-Su
Journal: Thorax (2021)

The biochemical mechanisms underlying lung function are incompletely understood.
Combined Drug Targeting of p53-dependent and -independent Pathways Depletes Myelofibrosis Hematopoietic Stem/Progenitor Cells
Authors: Min Lu, Lijuan Xia, Nada Elmansy, Cara Clementelli, Douglas Tremblay, Ronald Hoffman
Journal: Leukemia (2021)

Current therapy for myelofibrosis (MF) results in a limited prolongation of patient survival. In order to improve treatment outcomes, we developed a strategy to effectively deplete MF hematopoietic stem/progenitor cells (HSPCs). In the present study, an imipridone, ONC201, was combined with RG7112, an antagonist of MDM2, a p53 negative regulator, to activate downstream events of the p53 and TNF-related apoptosis-inducing ligand (TRAIL)/death receptor (DR) pathways. As compared to treatment with the individual drugs, the combination of ONC201 and RG7112 promoted greater degrees of apoptosis of MF CD34+ cells through activation of both p53-dependent and -independent pathways. Importantly, treatment with ONC201-RG7112 not only decreased the number of JAK2V617F+ and calreticulin mutated colonies assayed from MF CD34+ cells, but allowed for the persistence or appearance of JAK2 wild type colonies. Treatment with ONC201 combined with RG7112 could be a potentially effective strategy for treating MF patients.
Distinction of lymphoid and myeloid clonal hematopoiesis
Authors: Abhishek Niroula, Aswin Sekar, Mark A. Murakami, Mark Trinder, Mridul Agrawal, Waihay J. Wong, Alexander G. Bick, Md Mesbah Uddin, Christopher J. Gibson, Gabriel K. Griffin, Michael C. Honigberg, Seyedeh M. Zekavat, Kaavya Paruchuri, Pradeep Natarajan, Benjamin L. Ebert
Journal: Nature Medicine (2021)
The assessment of impact of covid-19 in patients with acute leukemia
Authors: V. Popov, M. O. Omer, L. Iliescu, M. Andreescu, D. Georgescu, F. Mihai, M. Popescu, C. Pirvu, A. Grigorie, A. Rus, M. D. B. Niculae, O. Constantin, A. Badea, A. Calen, O. Patrinoiu, S. Ciortan, C. Despan, G. Ofiteru, S. Ion, M. Balea, H. Bumbea
Journal: HemaSphere (2021)

Background: The severe acute respiratory syndrome coronavirus-2 (SARSCoV-2) was first reported in Wuhan, China in December2019 and represented the pathogen agent that induced COVID-19. The onset and evolution of COVID -19 is severe when is associated with another comorbidities. Patients with acute leukemia present high risk for severe form of COVID-19 Aims: The main objective was to evaluate the particularities of COVID-19 in patients with acute leukemia. Methods: Our study was prospective and included 49 patients with acute leukemia (27 male median age 64 and22 female median age 54,5) who also were SARS CoV2 positive between April2020- February2021 admitted in Hematology and Intensive Care Unit Departments of Colentina Clinical Hospital Bucharest. The diagnosis was established using molecular test for SARS-Cov2 Results: In the group was included 32 patients diagnosed with acute myeloid leukemia (AML), 9 patients with acute lymphoid leukemia (ALL), 6 patients with acut promyelocytic leukemia and2 patients with acute bifenotypic leukemia. Severe form of COVID-19 with ICU addmission was diagnosed in16 patients (32,17%), almost all of them (15 patients) had unfavourable evolution compared with non-ICU patients group with only1 deceased patient, p<0.0001. The recent chemotherapy followed by severe aplasia was the main negative factor that impacted patient evolution (rho=0.508, p=0.0002),13 patients admitted in ICU Department and12 patients in non-ICU. Severe pneumonia (more than 30% lung field) was diagnosed in17 patients with recent chemotherapy and 4 untreated patients. The type of leukemia or refractory status have not any impact of patient evolution. Antiviral therapy - Remdesivir rapidly introduced in patient's therapy was followed by favourable evolution. Summary/Conclusion: Patients with acute leukemia are negatively impacted by intensive chemotherapy during COVID-19 evolution. The key for good prognosis of these patients during COVID-19 are rapid diagnosis and antiviral therapy at the onset of the disease.
P50.03 A Real-World Cohort Study of EGFR TKIs in Patients with NSCLC with Uncommon EGFR mutations (UpSwinG)
Authors: S. Miura, T. Hsia, J. Hung, H.A. Jung, J. Shih, C. Park, S.H. Lee, T. Okamoto, H.K. Ahn, Y.C. Lee, Y. Sato, S.S. Lee, C. Mascaux, H. Daoud, A. Märten, S. Popat
Journal: Journal of Thoracic Oncology (2021)